KRTX - Karuna Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.68
+0.29 (+1.67%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close17.39
Open17.39
Bid16.50 x 1100
Ask20.00 x 1100
Day's Range16.80 - 17.95
52 Week Range11.24 - 29.00
Volume60,042
Avg. Volume88,227
Market Cap413.938M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-254.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.50
  • Business Wire

    Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update

    BOSTON-- -- Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019 Phase 1b clinical trials for the treatment of psychosis in Alzheimer’s disease and pain on track to commence by the end of 2019 Cash, cash equivalents and short-term investment balance of $161.6 million to fund development of novel ...

  • GuruFocus.com

    Karuna Therapeutics Inc (KRTX) President & CEO Steven M Paul Bought $230,400 of Shares

    President & CEO of Karuna Therapeutics Inc (NASDAQ:KRTX) Steven M Paul bought 10,000 shares of KRTX on 06/28/2019 at an average price of $23.04 a share.

  • Benzinga

    Karuna Therapeutics Opens Above IPO Price

    Karuna Therapeutics, Inc. (NASDAQ: KRTX ) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Karuna focuses on developing novel therapies to address disabling ...

  • Business Wire

    Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. In addition, Karuna has granted the underwriters a 30-day option to purchase up to 836,718 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

  • Benzinga

    Karuna Therapeutics IPO: What You Need To Know

    Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week.  The IPO Terms Boston, Massachusetts-based Karuna Therapeutics, ...